- Funding will accelerate development of wearable monitor to detect osteoarthritis-related pain in companion animals
- Backed by experienced seed investors including Irrus Investments, Pro-Vet and Stonehaven Incubate
- Seed financing planned for 2022 to further drive product development and commercialization
- Investment by Pro-Vet enables for commercialization in China and other Asian countries
Delaware, US, 4 October 2021 – AniV8, a leading developer of clinical sensor technology to diagnose and monitor diseases affecting companion animals, today announced the completion of its pre-seed funding round, which closed significantly above its original target. The funds raised will enable AniV8 to conduct larger clinical studies using its unique technology and accelerate product development and commercialization.